Parasitic worms, seen here, cause river blindness when transmitted to humans by flies
Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world.
New funding from the Global Health Innovative Technology Fund will allow scientists from the University of Liverpool’s Department of Chemistry, together with colleagues at the Liverpool School of Tropical Medicine and Japanese pharmaceutical company, Eisai, to develop new medication which is targeted at the bacteria Wolbachia.
River blindness (onchocerciasis) and elephantiasis (lymphatic filariasis) are caused by parasitic worms, and previous attempts to cure these diseases have focused on developing drugs to kill these parasites.
Left untreated, river blindness, where the worms are transmitted by flies, can leave people robbed of their sight, whereas elephantiasis, transmitted by mosquitos, causes extreme swelling in the limbs and genitals.
Attacking these bacteria causes the worms to die slowly or become sterile. The team, known as the Anti-Wolbachia Consortium (A.WOL), has already shown that a four to six week course of the antibiotic, doxycycline can deplete Wolbachia from parasitic worms to cure infection, which has led to the adoption of this treatment in many areas of the world.
The new funding will allow the creation of drugs which can be used in children and pregnant women and can be effective over the course of a week.
The development of the new drugs was achieved by screening over 60,000 compounds to test their ability to kill Wolbachia. With the new funding, the most promising drug candidates will proceed through advanced rounds of chemical modification and testing to identify compounds that have a good safety and efficacy profiles, ready to move into pre-clinical testing.
Medicinal chemist, Professor Paul O’Neill from the University said: “The relationship between these worms and the bacteria is their weakness.
“By targeting the Wolbachia we can safely remove the worms and the disease, and with a quicker acting drug, we can also develop a medicine which is more useful in areas where resources are scarcer and budgets tighter.”
You must be logged in to post a comment.
All recent news
Obituary: Benny Pollack
Risk factors associated with severe and fatal cases of COVID-19 identified
Architecture academics on the view from your lockdown window
COVID-19 and alcohol – a dangerous cocktail
University lockdown lecturer engages with new audience online
"Just because Boris Johnson and the Prince of Wales have had #Covid19 doesn’t mean the disease strikes all people equally"
New @bmj_latest piece by @livuniHLS Profs Dame Margaret Whitehead, Ben Barr & David Taylor-Robinson #healthinequalities #LivUniCovid https://go.shr.lc/2LU5Gdm
We are not “all in it together”—less privileged in society are suffering the brunt of the damage https://blogs.bmj.com/bmj/2020/05/22/covid-19-we-are-not-all-in-it-together-less-privileged-in-society-are-suffering-the-brunt-of-the-damage/
@felly500 @BWDDPH @martinmckee @AbdulRazaq_PH @SimonCapewell99 @ProfBambra
Dr @soozaphone on @LivUniPsyc's new ‘Coping with COVID podcast’ that provides psychological support to medical, allied health professions and nursing students working in the #NHS during the #COVIDー19 pandemic.
More info https://bit.ly/2A5IOET